Striae Distensae Clinical Trial
Official title:
Clinical Evaluation of Venus Versa SR Applicator Using Intense Pulsed Light on Skin Texture for Improving the Appearance of Striae Distensae
NCT number | NCT02452359 |
Other study ID # | CS0315 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | March 13, 2015 |
Est. completion date | March 31, 2017 |
Verified date | October 2020 |
Source | Venus Concept |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is intended to evaluate the effect of IPL treatment on the Striae Distensae. The study hypothesis is that the SR580 applicator will improve the appearance of Striae Distensae by at least 1 point on the Global Aesthetic Improvement ScaleI (GAIS) at 3 months follow-up compared to baseline in at least 50% of the study population.
Status | Terminated |
Enrollment | 54 |
Est. completion date | March 31, 2017 |
Est. primary completion date | February 15, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 24 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Able to provide written Informed Consent; 2. Healthy male or female, 24-65 years Fitzpatrick-Goldman skin type I-V; 3. Having visible Striae Distensae to be treated (abdomen/thighs); 4. Comply with the treatment/follow-up schedule and requirements; 5. Women of child-bearing age are required to be using a reliable method of birth control Exclusion Criteria: 1. Fitzpatrick-Goldman skin type VI; 2. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after breastfeeding; 3. Heavy smoker 4. Unable or unlikely to refrain from tanning 5. Use of photosensitive medication 6. Use of oral isotretinoin within 3 months 7. Any dermal/epidermal damage or disorder in treated area 8. Prior treatment in treated area within 3 months 9. Prior skin laser/light or another device treatment in treated area within 6 months 10. Prior use of collagen, fat injections or other methods of skin augmentation in treated area within 12 months 11. Prior use of Botox in treatment area within 6 months 12. Prior ablative resurfacing procedure with laser in treatment area within 12 months 13. Any other surgery in treated area within 9 months 14. Participation in a study of another investigational device or drug as per the Investigator's discretion 15. History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area 16. Showing symptoms of hormonal disorders (such as Melasma, Chloasma); 17. Concurrent inflammatory skin conditions, open laceration or abrasion of any sort on area to be treated during the course of treatment 18. Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study 19. Multiple dysplastic nevi in area to be treated 20. Having a bleeding disorder or taking anticoagulation medications 21. History of immunosuppression/immune deficiency disorders 22. Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer 23. Pigmented lesion in the treated area that appears cancerous 24. Significant concurrent illness, such as uncontrolled diabetes 25. Active infections in the treated area 28.Tattoo or permanent makeup at the treatment area. 29.Mentally incompetent, prisoner or evidence of active substance or alcohol abuse 30.Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study |
Country | Name | City | State |
---|---|---|---|
United States | Rosenberg Plastic Surgery | Beverly Hills | California |
Lead Sponsor | Collaborator |
---|---|
Venus Concept |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement in Striae Distensae Appearance | Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse. | 90 days following last IPL treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06000839 -
A Safety and Effectiveness Study of CELLBOOSTER® Lift (Stabilized Booster Complex Using CHAC Technology)
|
N/A | |
Completed |
NCT02601105 -
Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks
|
N/A | |
Completed |
NCT05461755 -
Treatment of Striae Distensae With Fractional Radiofrequency and Topical Tretinoin
|
Phase 2 | |
Recruiting |
NCT05827913 -
Efficacy and Safety of Polylevolactic Acid Injection Combined With 1565nm Non-ablative Fractional Laser in the Treatment of Striae Distensae
|
N/A | |
Completed |
NCT02126566 -
Multiclear Treatment for Striae Distensae - A Pilot Study
|
Phase 2 | |
Completed |
NCT03858543 -
Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae
|
Early Phase 1 | |
Completed |
NCT03390439 -
Treatment of Atrofic Striae With Percutaneous Collagen Induction Therapy Versus Fractional Nonablative Laser
|
N/A | |
Recruiting |
NCT04092881 -
Efficacy of Short Pulsed 1064 nm Nd-YAG Laser Versus 10600 nm Fractional CO2 Laser in Treatment of Striae Alba
|
N/A | |
Completed |
NCT02510768 -
A Study to Evaluate the Efficacy of ELAPR in Women With Striae Distensae Alba
|
Phase 1 |